Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Idexx (IDXX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2024.

WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, will now host its 2024 second quarter conference call and webcast at 9:00 am ET on Tuesday, August 6, 2024, to minimize conflicts with other industry earnings announcements. Individuals can access a live webcast of the conference call, transcript of prepared remarks, and the Q2 2024 Earnings Snapshot through a link on the IDEXX website, www.idexx.com/investors. An archived e.

Idexx (IDXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

WESTBROOK, Maine , July 30, 2024 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today published its 2023 Corporate Responsibility Report "Enhancing the Health and Well-being of Pets, People, and Livestock for 40 Years" highlighting progress against its corporate responsibility goals. The Care We Advance IDEXX brings clarity to the complex world of veterinary medicine through diagnostic insights and software solutions that support longer, fuller lives for pets and those who care for them.

IDEXX Laboratories' (IDXX) second-quarter 2024 results are likely to reflect the benefits of strong execution against the growth strategy.

IDEXX Laboratories is a $41 billion market cap giant in the diagnostics and research industry, with shares falling 13% since February. The company specializes in animal healthcare diagnostics, showing rapid growth and innovation in a high-growth market. Despite a lofty valuation, IDEXX's strong financials, consistent revenue growth, and long-term growth prospects justify a Buy rating.

WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2024 second quarter results for Tuesday, August 6, 2024, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. EDT on that day. Individuals can access a live webcast of the conference call, transcript of prepared remarks, and the Q2 2024 Earnings Snapshot through a link on the IDEXX website, www.i.

IDEXX's (IDXX) supply chain operations bear the brunt of geopolitical instability, including the current war in Ukraine.

IDEXX's (IDXX) new Catalyst Pancreatic Lipase Test is likely to support veterinarians globally in diagnosing pancreatitis.

The launch of the Catalyst® Pancreatic Lipase Test demonstrates IDEXX's Technology for Life strategy and will provide veterinarians with quantitative results at the point-of-care in less than 10 minutes  WESTBROOK, Maine , June 4, 2024 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, announces the launch of the Catalyst® Pancreatic Lipase Test, a single-slide solution for canine and feline patients suspected of pancreatitis. With the innovative load-and-go workflow of the Catalyst analyzers, the test can run effortlessly alongside chemistry profiles, leading to a faster path to diagnosis and enhanced patient outcomes.

Idexx (IDXX) reported earnings 30 days ago. What's next for the stock?

The modern pet industry is a testament to the amounts that pet owners and animal lovers are willing to spend on their furry companions. In 2023, U.S. consumers alone spent $147 billion in the pet industry.